According to a newly published market research report by 24LifeSciences, the global veterinary vaccine market was valued at USD 10.54 billion in 2024 and is projected to reach USD 17.48 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period 2025–2031.
Veterinary vaccines are immunobiological products designed to trigger protective immune responses in animals, preparing their immune systems to fight future infections. These products stimulate the production of antibodies that identify and destroy specific pathogenic organisms, thereby providing immunity that can lessen the severity or entirely prevent a range of infectious diseases. In essence, they are a critical tool in prophylactic healthcare for both livestock and companion animals, which is the focus of this market analysis.
Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/7433/veterinary-vaccine-market
The increasing global prevalence of zoonotic diseases and the surge in pet ownership remain the primary growth drivers for the veterinary vaccine market. The World Organisation for Animal Health (WOAH) reports that approximately 60% of known infectious diseases in humans can be spread from animals, making vaccination programs essential for public health. This risk is a primary driver for mandatory vaccination programs in both companion and food-producing animals, fueling market expansion.
Expanding global population and rising disposable incomes, particularly in emerging economies, are driving increased consumption of animal protein and a surge in pet adoption. The Food and Agriculture Organization (FAO) projects that global meat production will continue to grow steadily. This intensification of livestock farming requires robust vaccination schedules to maintain herd health and productivity, while the growing pet humanization trend leads to higher spending on preventive care for companion animals.
Technological advancements in recombinant DNA technology, vector vaccines, and marker vaccines have transformed the market by improving product efficacy, safety, and specificity. These advanced platforms allow for the differentiation between infected and vaccinated animals (DIVA), which is crucial for disease eradication programs. The development of thermostable vaccines is also improving accessibility in regions with limited cold chain infrastructure, expanding market reach.
Ongoing research exploring novel vaccine platforms, including mRNA technology applied to animal health, is further opening new growth avenues for the veterinary vaccine market, promising faster development times and enhanced immune responses.
Despite positive growth trends, the market faces notable challenges:
Stringent regulatory approval pathways in markets like the U.S. and Europe
Cold chain logistics and maintenance requirements, particularly in developing regions
Vaccine hesitancy and misinformation among some animal owners
High development costs associated with new vaccine technologies
Additionally, price sensitivity in the livestock sector and competition from local manufacturers in emerging markets have intensified competitive pressures, particularly in cost-sensitive segments.
Get the Complete Report & Table of Contents: https://www.24lifesciences.com/veterinary-vaccine-market-7433
The North American region, led by the United States, dominates the global veterinary vaccine market, accounting for approximately 36% of total market share. This leadership is driven by:
Advanced veterinary healthcare infrastructure and high pet care expenditure
Stringent food safety regulations requiring livestock vaccination
Strong presence of leading vaccine manufacturers and research institutions
High awareness of zoonotic disease prevention among consumers
Asia-Pacific represents the fastest-growing market, supported by expanding livestock production and rising companion animal ownership, while Europe remains a significant secondary market with strong regulatory frameworks.
By application, farm animals represent the largest and most critical segment due to the economic importance of preventing disease outbreaks in food production systems.
By product type, live attenuated vaccines hold a significant share owing to their ability to induce strong and long-lasting immunity, though inactivated vaccines are gaining traction for their safety profile.
The global veterinary vaccine market is highly consolidated, with the top five players collectively accounting for nearly 75% of global revenue. The competitive environment is shaped by R&D capabilities, product portfolios, regulatory expertise, and global distribution networks.
Key companies profiled in the report include:
Zoetis Inc.
Merck & Co., Inc.
Boehringer Ingelheim
Elanco Animal Health
Ceva Sant Animale
Virbac
Phibro Animal Health
and More
Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/veterinary-vaccine-market-potency-vaccine market-7433
Significant growth opportunities exist in emerging markets across Asia-Pacific and Latin America, supported by improving veterinary infrastructure and rising animal health awareness. Furthermore, the development of novel vaccines for companion animals, including those for chronic conditions and lifestyle diseases, is expected to generate new revenue streams and expand clinical adoption.
Download a FreeSample Report (PDF):
https://www.24lifesciences.com/download-sample/7433/veterinary-vaccine-market
Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/veterinary-vaccine-market-7433
24LifeSciences is a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.
| No comments yet. Be the first. |